Infamous Russian torrent site RuTracker is one of many pirate sites that are permanently blocked by the Russian authorities for failing to remove copyrighted content. However, when the site suddenly became accessible again this month, RuTracker took its own measures to block Russian users.

From: TF, for the latest news on copyright battles, piracy and more.

HONG KONG, Mar 23, 2022 - (ACN Newswire) - Kingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing greater health products and services in China, issued today a positive profit alert as it expects to record an approximately 155% to 160% increase in profit attributable to owners of the Company for 2021, as compared to RMB11.7 million for 2020.

The positive profit alert was based on preliminary assessment of the unaudited consolidated management accounts of the Group for 2021 and information currently available to the Board. The Board attributes the increase in profit mainly to the market recovering from the COVID-19 pandemic outbreak pushing up the turnover and gross profit of imported branded pharmaceutical and healthcare products distributed in China in 2021 by approximately 45% to 50% and approximately 65% to 70%, respectively, against the previous year. The management of the Company also adopted effective measures against the COVID-19 pandemic outbreak to reduce costs and improve efficiency, thus enhancing the Company's overall competitiveness.

Shenzhen Dong Di Xin Technology Company Limited, Kingworld Medicines' non-wholly owned subsidiary, is a manufacturer producing various medical devices including infrared thermometers. Affected by a drop in sales of anti-Pandemic devices, the company is expected to record an approximately 34% to 39% decrease in profit for 2021 as compared with the previous year.

About Kingworld Medicines Group Limited
Kingworld Medicines (stock code: 01110.HK) has devoted more than 20 years to developing a comprehensive greater health industrial supply chain system. Its business covers over 34 provinces and municipalities in China, and it is among the Top 100 Import Enterprises of Pharmaceutical and Healthcare Products and Top 5 Sales of Imported Chinese Patent Medicine in the country. In-keeping with the new normal of consumption upgrade, it has constructed a complete online and offline new retail ecosystem. Its subsidiary Shenzhen Kingworld Medicines is a reputed distributor of branded pharmaceutical and healthcare products imported from overseas, including Nin Jiom Loquat Herbal Cough Syrup, Taiko Seirogan, Kingworld Imada Red Flower Oil, and Culturelle probiotics from the United States, etc., in the China market.

For further information, please visit http://www.kingworld.com.cn .



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing greater health products and services in China, issued today a positive profit alert as it expects to record an approximately 155% to 160% increase in profit attributable to owners of the Company for 2021, as compared to RMB11.7 million for 2020.

Here are the top trending news from the world of technology 1) Elon Musk unveils Tesla’s first European Factory with Fanfare Tesla’s CEO and founder Elon Musk on Tuesday unveiled company’s Gigafactory in Germany. This is a milestone moment for the electric vehicle manufacturer as this is its first factory in the Europe. To mark [...]

The post Elon Musk unveils Tesla’s first European Factory with Fanfare appeared first on Platform to Showcase Innovative Startups and Tech News.

Intro The SafetyDetectives cybersecurity team uncovered a data exposure affecting the Japanese medical Q&A service Doctors Me. Doctors Me is a website that provides customers with on-demand access to professional medical advice. An Amazon S3 bucket owned by the company was left open without proper access authorization and authentication controls in place, exposing sensitive data for […]

The post FDA Guidance on Simulated-Use Human Factors Validation Testing: Data Collection appeared first on RegDesk.

President Joe Biden on Monday warned of Russian cyberattacks against the US — making his most prominent alert yet about what he called new intelligence regarding the Putin regime’s plans. “The more Putin’s back is against the wall, the greater the severity of the tactics he may employ … one of the tools he’s most […]

The latest issue of Music & Copyright is now available for subscribers to download. Here are some of the highlights. Streaming and physical gains boost recorded-music trade sales to a seventh straight annual increase International music trade body the IFPI has reported a particularly positive set of results for the global recorded-music sector. Following on … Continue reading New issue of Music & Copyright with Indonesia report →

The Spanish ombudsman has been receiving complaints about cryptocurrency and how some Spanish citizens investing in these vehicles have lost everything. In his annual report, Angel Gabilondo recognized the rise of cryptocurrencies as a new problem due to the little or no regulation crypto sees in the country. In the same way, the EU has […]

After a substantial overhaul in February, Cyberpunk 2077 has received a new update that continues to tweak several lingering issues inside of the game. While it's not as massive as the previous update, there are a significant number of improvements that have been added to the sci-fi sandbox according to the patch notes.

In the gameplay department, issues related to missing loot, broken animations, and teleporting wrecked cars have been fixed. Console-specific fixes include addressing corrupted saves being imported from PS4 to PS5, Xbox Series X|S controller disconnects will no longer result in a player being stuck, and wet roads should have an accurate amount of reflection on the PS5 version that's comparable to the PC edition of the game.

Bugs in quests such as Automatic Love, Epistrophy, and Path of Glory have also been cleaned up, and your vehicle should spawn closer to V when it's summoned. You can see the full list below of all the fixes. While Cyberpunk 2077 and its saucy Johnny Silverhand content are in a better state currently, developer CD Projekt Red is looking to the future by revisiting its past. The studio announced this week that a new Witcher game is in development and will be built using Unreal Engine 5, but it won't be exclusive to the Epic Games Store on PC.

Cyberpunk 2077 won't be making a graphical engine switch either, as CDPR will continue to use REDEngine for the game's upcoming expansion.

Cyberpunk 2077 Update 1.52 Patch Notes

Gameplay

• Fixed an issue that could cause wrecked cars or multiple Nomad cars to spawn in traffic when driving fast.
• Fixed an issue where first equip animation could be played repeatedly after recovering a throwing knife.
• The Laminate-armor Media Ballistic Vest can now be found as loot in Japantown.
• Fixed an issue where the recon grenade highlighted non-hostile crowd NPCs.
• Fixed an issue where after using the Take Control quick-hack on a device, the camera axis was inverted when zoomed in.

Quests

• Player won't be able to purchase again an apartment makeover they already own anymore.
• Added the showering interaction to the Nomad Camp.
• It won't be possible to hack the Northside apartment before completing Act 1 anymore.
• Fixed an issue where Open World combat events and some scenes could remain disabled after visiting Afterlife until the player fast traveled within Watson.
• Automatic Love - Walking into a wall in the elevator in Megabuilding H8 will no longer cause instant death.
• Blistering Love - Fixed an issue where Johnny could despawn if player left the booth before interacting with the projector, blocking progress.
• Cyberpsycho Sighting: Demons of War - Fixed an issue where it wasn't possible to progress past the "Search the area to collect information" objective.
• Epistrophy - Fixed an issue where the quest could reappear in the Journal instead of being marked as failed after player failed to retrieve any of the cabs.
• I Fought the Law - Fixed an issue where River could drive out of the market area erratically and push V out of world bounds.
• Life During Wartime - Fixed an issue where selecting a blue dialogue option twice upon arriving on the crash site blocked progression.
• Path of Glory - Optional objective "Get dressed" will no longer be incompletable if player collected the clothes before it appeared.
• The Information - Fixed an issue where the doors to Lizzie's were closed during the hours they should be open, blocking progression.
• The Ride - Fixed an issue where Dex's car was swerving left and right when driving away.
• With a Little Help from My Friends - Fixed an issue where holocalls and text messages could be blocked if player told Saul about Panam's plan while the Nomads were driving away.

Open World

• Fixed an issue where summoned vehicles could be spawned far away from the player.
• Suicidal Corpos in Corpo Plaza will no longer stand up after the fall.
• Fixed an issue where an Assault in Progress in Arroyo wasn't visible on the map, hindering progress in The Jungle achievement.
• Gig: Goodbye, Night City - Fixed an issue where the quest didn't trigger after approaching the area.
• Gig: No Fixers - Fixed an issue where the "Park Iris' car in the garage" optional objective didn't complete if player stopped in front of the garage.
• Gig: Playing for Keeps - Fixed an issue where all the enemies in the casino were set to Friendly.
• Murk Man Returns Again Once More Forever - Fixed an issue where the Rayfield Caliburn didn't spawn.

User Interface

• Added a quest tag to fixer rewards when they're first found in the stash.
• Opening menus while reading a shard will no longer block the game.
• It won't be possible to change the position of the marker when a time skip is in progress anymore.
• Fixed an issue where the loot UI could flicker and change before picking up the item.
• Fixed an issue where the English text "A Favor for a Friend" would be displayed regardless of the language version instead of the correct quest name for some tracked quests.

Visual

• Fixed animations and missing or displaced objects in various scenes.
• Fixed some issues with animation occurring when performing an aerial takedown using the Hidden Dragon perk.
• Fixed an issue where sandstorms could appear in scenes they weren't supposed to.
• Fixed an issue where foliage was not affected by different weather conditions.
• Polycarbonate Sport Sunglasses will no longer be visible when switching between Third Person Mode and First Person Mode while driving.

Console-specific

• Memory improvements and crash fixes on next-gen consoles.
• Minor UI optimizations.
• [PlayStation 5] Importing a save while not connected to the PlayStation Network will no longer block the option to continue the game.
• [PlayStation 5] Fixed an issue where a corrupted save was created when player tried to import a PlayStation 4 save when no saves were exported.
• [PlayStation] Fixed an issue where the "Press [Options Button] To Continue" screen registered pressing the button with a delay.
• [PlayStation 5] Wet roads will now be as reflective as on the PC version.
• [PlayStation 5/Xbox Series X] Changing the preset in Video settings will no longer set all the Graphics options to ON automatically.
• [Xbox One/Xbox Series X] Disconnecting the controller and entering the pause menu at the same time will no longer result in player being stuck.

Stadia-specific

• Enabled aggressive crowds on Stadia.

Recently, Epic had announced that they will be donating all profits from the sales in the first two weeks (i.e. March 20th to April 3rd) of Chapter 3 season 2 for humanitarian relief for people affected by the war in Ukraine.  Season 2 launched on March 20 at around 08:00 am CT and as of […]

The post Epic raises $36 million in 24 hours via Fortnite for humanitarian relief in Ukraine appeared first on TalkEsport.

TOKYO, Mar 22, 2022 - (JCN Newswire) - The NEC Group would like to express our sympathies to all who are impacted by the tragic situation in Ukraine, and our thoughts are especially with the family of NEC group employees who call that region home. We sincerely hope that peaceful, safe and secure conditions will return as soon as possible. "Uncompromising Integrity and Respect for Human Rights" is part of the NEC Group's Principles of the NEC Way that define the basis of our actions and behaviors, and we condemn any unlawful use of force that violates human rights.

Netcracker Technology, a U.S.-based subsidiary of NEC Corporation, operates software development sites in Ukraine. Netcracker Technology has implemented a series of aid and support initiatives for its employees in Ukraine and their families, including evacuation support and provision of housing, food, water, goods and supplies. As of today, more than 700 of our Ukrainian employees and their families have been relocated to safer locations within Ukraine and abroad.

In addition to complying with the regulations of the Government of Japan and the international community, the NEC Group has suspended all future sales of products and services, as well as future investments in Russia.

Further, the NEC Group will donate five hundred thousand euros to the United Nations World Food Programme (WFP) for humanitarian assistance for those affected by the crisis in Ukraine and its surrounding areas. In addition, each NEC Group company is raising donations from employees around the world.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comThe NEC Group would like to express our sympathies to all who are impacted by the tragic situation in Ukraine, and our thoughts are especially with the family of NEC group employees who call that region home.

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Highlights
-- The group's turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million;

-- Sales coverage increased to around 10,500 hospitals and 2,110 pharmaceutical stores in the PRC;

-- Obtained an approval for the registration and commercialisation of the preservative-free unit-dose Moxifloxacin Hydrochloride Eye Drops in the PRC;

-- Significant progress in R&D program, 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage as the below:
SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021;
Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC);
Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC);

-- Holds a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents;

-- Completed the acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules.

Significant progression in Financial Performances

Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties. For the year ended 31 December 2021, the Group recorded a turnover growth of 67.4% to approximately HK$1,637.7 million as compared to approximately HK$978.1 million in 2020, indicating a strong recovery to the pre-COVID-19 operating level. In tandem with the increase of turnover, the Group achieved an increase of 58% in after-tax profit to approximately HK$346.0 million as compared to approximately HK$218.9 million in 2020.

Turnover of Ophthalmology and Surgical Segments Surged 60.6% and 72.6% respectively
The Group's turnover is primarily made up from the segments of Ophthalmology and Surgical (wound care and healing). The core products that are of current growth driver under each segment are:

1. Ophthalmology - Beifushu series (Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops and Shilishun(Iodized Lecithin Capsules); and

2. Surgical (Wound care and healing) - Beifuji series (Beifuji spray, Beifuji lyophilised powder and Beifuxin gel), Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules.

The sectoral turnover of Ophthalmology and Surgical is approximately 41.1% and 58.9% of the Group's turnover, respectively. The combined turnover of the Group's flagship biologics, Beifushu series and Beifuji series, the basic fibroblast growth factor (bFGF) based biologic drugs, represented about 84.3% of the Group's total turnover, of which Beifushu series and Beifuji series accounted for 26.1% and 58.2% of the Group's turnover, respectively. The remaining 15.7% of the Group's turnover is mainly contributed from sales of Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Shilishun Iodized Lecithin Capsules, Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules, collectively. Ophthalmology segment contributed approximately HK$673.3 million to the Group's turnover for the year ended 31 December 2021, representing an increase of 60.6% as compared to approximately HK$419.2 million in 2020. Surgical segment recorded a total turnover of approximately HK$964.4 million for the year ended 31 December 2021, representing an increase of 72.6% as compared to approximately HK$558.9 million in 2020. The increase was attributable to the resumption of clinical operations in hospitals to normalcy in the PRC and the expansion of sales.

The selling of Xalatan Eye Drops and Xalacom Eye Drops would be discontinued in 2022 that contributed approximately 2% to the Group's gross profit for the year ended 31 December 2021.

The Board proposed a final dividend of HK$0.055 (2020: HK$0.05) per ordinary share to be approved at the upcoming annual general meeting of the Company.

Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges. Our part of the world has been affected by extended lockdowns and border closures under COVID zero regime, even as other regions begun to reopen. Despite yet another difficult year inflicted by the pandemic of COVID-19 on us all, the tenacity, drive and leadership in our DNA was able to deliver greater stakeholder value. The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021. This is a testament that the Group's business is resilient and was able to recover swiftly to the pre-COVID-19 level after the normalcy of the clinical operations of hospitals resumed in the PRC since September 2020."

Significant Business Development Activities

The Group is committed to pragmatically investing in new products and technologies to strengthen the Group's product and R&D pipeline as near to mid-term growth driver in ophthalmology and long-term plan for new therapeutics in oncology. During the year under review, major investments in ophthalmic products are outlined as follows:

Investment in Ophthalmology

Significant progress for SkQ1's second phase 3 clinical trial
In 2018, the Group entered into a co-development agreement with Mitotech S.A. ("Mitotech") and Mitotech LLC for the United States Food and Drug Administration (the "US FDA") phase 3 clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease. As disclosed in the announcement of the Company dated 24 February 2021, positive outcome was achieved during second phase 3 clinical trial (VISTA-2). The clinical trial study repeated statistically significant positive results on key predefined secondary end-point (Central Corneal Fluorescein Staining). The Board is enthusiastic about the read-out of clearing of central staining of the cornea (defined as zero staining in central cornea), which reveals the potential of SkQ1 in addressing oxidative stress in dry eye diseases. Following the positive trial outcome of VISTA-2, Mitotech has planned a pivotal trial (VISTA-3), which will commence once Mitotech's management team has fully assessed there is no potential disruption to trial centres and patient recruitment during the ongoing COVID-19 pandemic. However, recent developments in Ukraine have led to governments and industries reacting to business relationships with Russia in a way that could potentially induce delays in Mitotech's VISTA clinical trial program.

HLX04-O approved for phase 3 clinical trial
In 2020, the Group entered into a co-development and exclusive license agreement with Shanghai Henlius Biotech, Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor ("anti-VEGF") as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration ("wet-AMD"). As at the date of 22 March 2022, the recombinant anti-VEGF humanised monoclonal antibody injection HLX04-O ("HLX04-O") for the treatment of wet-AMD has been approved to commence the phase 3 clinical trial in Australia, the United States, Singapore, Russia, Serbia and European Union countries such as Hung ary, Spain, Latvia, the Czech Republic and Poland. Also, the first patient has been dosed in a phase 3 clinical study for HLX04-O for the treatment of wet-AMD in the PRC.

Ophthalmology business is expected to be further strengthened by the acquisition of Shilishun Iodized Lecithin Capsules

The successful acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules will enable the Group to strengthen its ophthalmology business.

Market Development

Robust Market Access Capability
Over the years, the Group has been relentlessly investing in establishing and strengthening its market access capability. As at 31 December 2021, the Group maintains a network of 43 regional sales offices in the PRC and a total number of about 1,265 sales and marketing representatives, out of which 64% are full-time employees and 36% are on contract basis or from appointed agents.

More Extensive Healthcare Network for Product Prescription
During the year under review, the Group's therapeutic products are being prescribed in more than 10,500 hospitals and medical providers, coupled with approximately 2,110 pharmaceutical stores, which are mainly located in the major cities, provinces and county cities in the PRC.

Further Investments to Strengthen Competitiveness and Customer Base
For achieving a sustainable traction on growth for currently marketed products as well as for near-term to mid-term new products being commercialised, the Group initiated investments to improve its competitiveness and widen its customer base under the following plans:

-- Investing in clinical observation programs for affirming additional clinical indications of its commercialised products;
-- Reaching out to market in lower-tier cities;
-- Cultivating pharmaceutical stores, where possible, as complementary sales channel; and
-- Building on-line platform for medical consultation and e-prescription for patients with chronic diseases under its healthtech initiative.

The Group has initiated its market access expansion to Southeast Asian countries by setting up a base and expanded its presence in Singapore since 2020.

Research and Development

The Group renewed its R&D's vision, emphasising the dedication to science and innovation, with a mission to develop therapeutics that would meet unmet clinical and/or commercial needs. The Group concurrently kick-started a 5-year (2021 to 2025) R&D's development plan to further strengthen its R&D capability and its position in Ophthalmology.

As at 31 December 2021, there are 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage. The 3 ophthalmology programs listed below are targeted as mid-term growth driver.

1. EB11-18136P: SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021

2. EB11-15120P: Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC)

3. EB12-20145P: Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC)

As at the date of this announcement, the Group has obtained a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents.

The Group currently has diversified its R&D resources to multiple research sites in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore which supports not only our pursuit for new therapeutics but also our acquisition of global talent.

Prospects

Looking ahead, the Group will continue to monitor the circumstances under the uncertainty of COVID-19 in 2022. Its strong team spirit and dynamic leadership have provided it with the capacity to navigate these turbulent times, and capture any opportunities in the ever changing world. The Group remains highly dynamic in delivering positive results in the coming year.

"COVID-19 remains a major concern in 2022 globally. We continue to monitor the situation and will take appropriate actions to overcome any unforeseen challenges. Barring the unforeseen circumstance, the Group remains focus on executing its plans and delivering progressive results. I would like to take this opportunity to express my sincere gratitude to all stakeholders, business associates and valued customers for the trust, support and cooperation accorded to us, and each and every member of the Group for their relentless efforts rendered in shaping the Group into being a progressive and promising pharmaceutical player.", said Mr. Patrick Ngiam.

Full version of Essex's FY2021 Annual Results Announcement can be downloaded at: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0322/2022032200780.pdf

About Essex Bio-Technology Limited (Stock Code: 1061.HK)
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun Iodized Lecithin Capsules etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Media Enquiry:
Strategic Financial Relations Limited (Website: http://www.sprg.com.hk)
Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320 yan.li@sprg.com.hk
Jill Cheung +852 2114 4870 jill.cheung@sprg.com.hk
Media: media@essex.com.cn

Investor Enquiry:
Investor Relations: investors@essex.com.cn


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEssex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.